Cerenome is trading at $1.80, up 5.26%, with no clear company-specific catalyst identified for the November 3 move.

  • The latest company announcement located was October 29: completion of enrollment in its Phase 2 ReSPECT-GBM trial, with topline data expected in mid-2027. That prior news does not establish a reason for the gain.
  • Market indices are mixed, so broad-market direction does not clearly explain the move.